At Pfizer Oncology, our mission is to "Outdo Cancer" by developing transformative therapies that make a meaningful impact for patients. Pfizer Oncology currently boasts an industry-leading portfolio spanning genitourinary (GU) cancers—including bladder and prostate—as well as breast, hematology-oncology, gastrointestinal-oncology, and thoracic cancers. The US Prostate Cancer business is one of the largest and fastest-growing segments within Pfizer, anchored by a multibillion-dollar portfolio that includes XTANDI, ORGOVYX, and TALZENNA. Building on this strong foundation, the team is now preparing for the anticipated launch of Mevrometostat. Mevrometostat is an innovative therapy in late-stage development, currently being evaluated in combination with enzalutamide for the treatment of metastatic Castration-Resistant Prostate Cancer (mCRPC) and metastatic Castration-Sensitive Prostate Cancer (mCSPC). This launch represents a pivotal opportunity to further expand Pfizer leadership in Prostate Cancer. This role will be responsible for spearheading the US launch of Mevrometostat, ensuring robust launch readiness and driving a successful market introduction by leading the Mevrometostat US launch asset team and overseeing the strategic development and execution of HCP strategies and initiatives. Close collaboration with Global Marketing and US cross-functional partners is essential for developing and executing the US go-to-market launch strategy. The position demands launch experience, strong strategic and analytical thinking, creativity, sound decision-making skills, and a proven track record of success in a team-based environment while managing multiple, competing priorities.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level
Number of Employees
5,001-10,000 employees